Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

AbCellera Biologics (ABCL) Non-cash Items (2021 - 2022)

AbCellera Biologics filings provide 2 years of Non-cash Items readings, the most recent being $113.4 million for Q4 2022.

Quarterly Non-cash Items rose 112960.82% to $113.4 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $113.4 million through Dec 2022, up 112960.82% year-over-year, with the annual reading at $113.4 million for FY2022, 112960.82% up from the prior year.
Non-cash Items hit $113.4 million in Q4 2022 for AbCellera Biologics, up from $928192.0 in the prior quarter.
Across five years, Non-cash Items topped out at $113.4 million in Q4 2022 and bottomed at $100300.0 in Q4 2021.